Abdul A. Waheed, Ph.D.

Abdul A. Waheed, Ph.D.
Associate Scientist

Team Member of:

Dr. Waheed’s research is focused on understanding the role of host factors in human immunodeficiency virus type 1 (HIV-1) particle assembly and release. Several host factors are involved in late stages of the retroviral replication cycle. Understanding the role that cellular proteins and lipids play in HIV-1 assembly and release could lead to the design of novel drugs that target and disrupt these interactions, resulting in inefficient virus release and a block to virus replication.

Several cellular restriction factors inhibit HIV-1 replication both at early and late stages. To counteract these restriction factors, viruses have evolved antagonistic accessory proteins. We are interested in identifying cellular proteins involved in counteraction of host-restriction factors by viral proteins.

Areas of Expertise

1) virology, 2) retroviruses, 3) virus assembly, 4) cell biology, 5) host factors, 6) small-molecule inhibitors

Contact Info

Abdul A. Waheed, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 535, Room 108B
Frederick, MD 21702-1201
Ph: 301-846-1739

Vpu Counteraction of Host Restriction Factor Tetherin

There are several host restriction factors that protect mammalian cells from viral infection. Tetherin (also known as CD317 or BST2) is an interferon-inducible type II transmembrane protein that prevents the release of a variety of enveloped viruses by directly tethering the virions on the cell surface. Viruses have evolved mechanisms to counteract these host restriction factors. HIV-1 accessory protein Vpu, an 81-amino-acid integral membrane protein, counteracts tetherin activity and enhances virus particle release by downregulation of tetherin.

The antagonism of human tetherin by Vpu is associated with proteasome- and lysosomal-mediated degradation. The Vpu-mediated degradation of tetherin is cell type specific, as our recent studies show Vpu markedly increases tetherin expression in agm kidney (COS) cells, apparently by sequestering it in an internal compartment that bears lysosomal markers.

To further understand the mechanism of Vpu-mediated tetherin regulation, we carried out yeast two-hybrid screening using full-length Vpu as bait to identify Vpu-interacting proteins. We have identified five Vpu-interacting proteins and are currently studying the role of these Vpu-interacting proteins in tetherin regulation.

High-Throughput Screening for Small-Molecule Inhibitors of HIV-1 Budding

Budding of viruses from the plasma membrane of infected cells is required for spreading infections, and expression of Pr55Gag is necessary and sufficient for the production of virus-like particles. For HIV-1, the budding process requires a direct interaction between the Pro-Thr-Ala-Pro (PTAP) motif in the p6 domain of Gag and the cellular endosomal sorting protein Tsg101. Mutation of the PTAP motif or depletion of Tsg101 severely disrupts HIV-1 budding. Thus, the Gag-Tsg101 interaction is essential for efficient HIV-1 release; disruption of this interaction could potentially serve as a therapeutic target for the development of novel drugs against HIV-1.

We have developed a fluorescence polarization (FP)-based assay to monitor the interaction between PTAP-containing peptide and the ubiquitin E2 variant (UEV) domain of Tsg101. Using this PTAP-Tsg101 binding assay, we performed quantitative high-throughput screening (qHTS) of ~380,000 compounds from the Molecular Libraries Small Molecule Repository (MLSMR) and picked about 100 active compounds that inhibit PTAP-Tsg101 interaction. We are currently testing the activity of these compounds in cell-based assays to identify potential inhibitors of HIV-1 budding.

NIH Scientific Focus Areas:
Cell Biology, Microbiology and Infectious Diseases, Molecular Biology and Biochemistry, Virology
View Dr. Waheed's PubMed Summary.

Selected Key Publications

  1. Waheed AA, MacDonald S, Khan M, Mounts M, Swiderski M, Xu Y, Ye Y, Freed EO.
    Sci Rep.. 10: 1038/srep24934, 2016. [ Journal Article ]
  2. Waheed AA, Ablan SD, Roser JD, Sowder RC, Schaffner CP, Chertova E, Freed EO.
    Proc Natl Acad Sci U S A. 104: 8467-71, 2007. [ Journal Article ]
  3. Waheed AA, Ablan SD, Mankowski MK, Cummins JE, Ptak RG, Schaffner CP, Freed EO.
    J Biol Chem. 281: 28699-711, 2006. [ Journal Article ]
  4. Johnson EN, Seasholtz TM, Waheed AA, Kreutz B, Suzuki N, Kozasa T, Jones TL, Brown JH, Druey KM.
    Nat Cell Biol. 5: 1095-103, 2003. [ Journal Article ]
  5. Waheed AA, Shimada Y, Heijnen HF, Nakamura M, Inomata M, Hayashi M, Iwashita S, Slot JW, Ohno-Iwashita Y.
    Proc Natl Acad Sci U S A. 98: 4926-31, 2001. [ Journal Article ]

Dr. Abdul Waheed is an Associate Scientist in Dr. Eric Freed's lab in the Virus-Cell Interaction Section, HIV Drug Resistance Program, NCI-Frederick.  He received his Ph.D. in Membrane Biochemistry from the University of the Ryukyus, Okinawa, Japan in 1999.  During his postdoctoral training at Tokyo Metropolitan Institute of Gerontology, Tokyo, Dr. Waheed showed the specific binding of theta-toxin (perfringolysin O) to cholesterol in lipid rafts.  He joined the National Institute of Diabetes and Digestive and Kidney Diseases in 2001, where he worked on the role of lipid rafts in G-protein signaling.  Since 2003 he has been working on host-factors involved in HIV-1 replication and small-molecule inhibitors of HIV-1 replication in the Freed lab.  Dr. Waheed was appointed as Lead Guest Editor in 2020 for a special issue of Viruses on Molecular Determinants of Enveloped Virus Assembly, in 2014 for a special issue of Current Topics in Medicinal Chemistry on Current and Emerging Drug Targets for Human Immunodeficiency Virus, and in 2012 for a special issue of Molecular Biology International on Host-Pathogen Interactions of Retroviruses.  He also serves as an Editorial Board member of Antivirals and Antiviral Therapy, International Journal of Virology and AIDS, Journal of Virology and Antiviral Research, and The Scientific World Journal.  Dr. Waheed was promoted to Staff Scientist in 2016 and Associate Scientist in 2019.